UB405
TargetsBTK/LYN
IndicationsChronic lymphocytic leukaemia; Small lymphocytic lymphoma; Diffuse large B-cell lymphoma
ClinicalCN - Pre-PCC
TherapeuticsOncology
ModalitiesSmall Molecule
Exclusive Summary
- • Reversible non-covalent dual BTK/ LYN inhibitors target both BTK-dependent and BTK- independent B-cell receptor (BCR) signaling pathways.
- • Potential to treat resistance mutations of BTK degraders.
- • Better in vivo efficacy in DLBCL than LOXO-305
我们能如何帮助您？
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →